PMC Regional Hospital Brings to the Region MOSES 2.0, A Next-Generation Treatment for Enlarged Prostate and Kidney Stones

HoLEP with MOSES 2.0 improves the efficiency of enlarged prostate procedures, offering 43% faster enucleation and 54% faster hemostasis.¹ This results in shorter length of hospital stay, better surgical outcomes and higher patient satisfaction. Kidney stone removal with MOSES 2.0, meanwhile, offers 20% faster procedures and 33% faster stone ablation while minimizing incidents of ureteral stone migration into the kidney,² improving quality of care and minimizing treatment burdens for patients.

“As a physician-owned hospital, we are passionate about taking a leading role by adopting technologies that elevate the quality of care,” said Dennis Medley, CEO. “The implementation of MOSES 2.0 will allow us to offer patients strong clinical outcomes with remarkable efficiency, benefiting patients, clinicians, and the hospital at large. We evaluated the top laser platforms on the market and determined that MOSES 2.0 was the only device able to meet all of our patients’ urological needs.”

“Enlarged prostate and kidney stones are two common problems that severely impact quality of life and present significant treatment burdens,” said Medley. “The MOSES 2.0 makes prostate and kidney stone surgeries faster and more streamlined, improving the care experience for both patients and practitioners.”

About PMC Regional Hospital
www.pmcindiana.com
PMC Regional Hospital, designed and owned by doctors who live and practice in the Kentuckiana region, is located in New Albany, Indiana. PMC opened its doors in 2008, with a mission to provide the highest quality patient care and maximizing benefits to both patients and physicians. PMC offers physicians a unique regional opportunity: the ability to deliver high quality clinical care in an independent setting that ensures greater quality control, lower costs, and added benefits potential.

References

1. Nevo et al. Holmium Laser Enucleation of the Prostate Using Moses 2.0 vs Non-Moses. A Randomized Controlled Trial: BJU Int. 2020 Oct 7. doi: 10.1111/bju.15265
2. Andonian et al. Double-blinded Prospective Randomized Clinical Trial Comparing Moses and Regular Modes of Holmium Laser Lithotripsy: J Endourol. 2020 Apr 3. doi: 10.1089/end.2019.0695

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005059/en/